Moderna Expects Vaccine Data For Kids Ages 2-5 By March

The company is also evaluating boosters for 12- to 17-year-olds as Covid-related hospitalizations for children reach record levels.

Read the full post on Forbes - Healthcare

Mason Bissada, Forbes Staff